PREPAID EXPENSES, OTHER CURRENT ASSETS AND RELATED-PARTY RECEIVABLE

Prepaid expenses and other current assets consist of the following (in thousands):



	2018		2017
Deposits	$	1,087	$	21,940
Other prepaid expenses and receivables	12,476		4,208
Deferred costs	1,951		1,301
Prepaid insurance and property taxes	2,666		2,580
VAT/GST receivable	5,072		8,097
Deferred tax charge	1,180		1,326
Other	1,548		1,834
	$	25,980	$	41,286

Related-party receivables consist of the following (in thousands):



	2018		2017
Third-party receivables due from Pfizer	$	4,904	$	36,425
HIS business acquisition related	15,233		62,382
	$	20,137	$	98,807

Third-party receivables due from Pfizer relates to trade accounts receivable that have already been collected from customers by Pfizer on our behalf. HIS business acquisition related receivables include amounts due from Pfizer related to the manufacturing and supply agreements and deferred close entities and amounts we prepaid to Pfizer for operational expenses under the transition services agreement.

Pfizer became a related party to us when we issued 3.2 million shares of our common stock as partial consideration for the acquisition of HIS. As of December 31, 2018, Pfizer has sold all of its shares of our common stock. In connection with the sale of 2.5 million of the shares Pfizer held, we incurred a one-time fee payable to Pfizer in the amount of $8.0 million included in restructuring, strategic transaction and integration expense in our consolidated statement of operations.

On February 3, 2017, we entered into a transitional services agreement and two Manufacturing and Supply Agreements ("MSA's") with Pfizer, (see Note 16, Collaborative and Other Arrangements). During 2018, the revenue for goods manufactured for Pfizer was $78.2 million and the cost of product manufactured by Pfizer for us was $81.0 million. During 2017, the revenue for goods manufactured for Pfizer was $72.4 million and the cost of product manufactured by Pfizer for us was $70.2 million.